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Background. Reduced bone mineral density (BMD) is common in adults infected with human immunode-
ficiency virus (HIV). The role of proximal renal tubular dysfunction (PRTD) and alterations in bone metabolism
in HIV-related low BMD are incompletely understood.
Methods. We quantified BMD (dual-energy x-ray absorptiometry), blood and urinary markers of bone me-
tabolism and renal function, and risk factors for low BMD (hip or spine T score, 1 or less) in an ambulatory
care setting. We determined factors associated with low BMD and calculated 10-year fracture risks using the World
Health Organization FRAX equation.
Results. We studied 153 adults (98% men; median age, 48 years; median body mass index, 24.5; 67 [44%]
were receiving tenofovir, 81 [53%] were receiving a boosted protease inhibitor [PI]). Sixty-five participants (42%)
had low BMD, and 11 (7%) had PRTD. PI therapy was associated with low BMD in multivariable analysis (odds
ratio, 2.69; 95% confidence interval, 1.09–6.63). Tenofovir use was associated with increased osteoblast and os-
teoclast activity ( ). The mean estimated 10-year risks were 1.2% for hip fracture and 5.4% for any majorP .002
osteoporotic fracture.
Conclusions. In this mostly male population, low BMD was significantly associated with PI therapy. Tenofovir
recipients showed evidence of increased bone turnover. Measurement of BMD and estimation of fracture risk may
be warranted in treated HIV-infected adults.
Low bone mineral density (BMD), including premature
osteopenia and osteoporosis, is common in persons
infected with human immunodeficiency virus (HIV)
[1–5]. A review of cross-sectional studies found that
HIV-infected adults had a 6.4-fold increased odds ratio
(OR) of osteopenia and a 3.7-fold increased OR of
osteoporosis compared with uninfected controls [1].
“Classic” risk factors identified were low body mass
index, weight loss, corticosteroid use, and smoking, to-
gether with the duration of HIV infection [2, 6].
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Dynamics in BMD depend on the balance between
osteolytic activities of osteoclasts and regenerative
activities of osteoblasts. Reductions in BMD directly
correlate with the risk of bone fractures. Every re-
duction of 1 standard deviation (SD) in vertebral
BMD, for example, resulted in a 2-fold increased risk
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of vertebral fracture [7]. The mechanism of low BMD in HIV-
infected adults is uncertain, as are the relative effects of classic
risk factors, HIV itself, and specific antiretroviral therapies on
BMD and fracture risk in treated HIV-infected patients.
Particular drugs and drug classes have been associated with
low BMD. Tenofovir (TDF) is a nucleotide analogue reverse-
transcriptase inhibitor shown to reduce BMD [8, 9]. Low BMD
has been attributed to the use of HIV protease inhibitors (PIs),
but other antiretrovirals have also been implicated [10, 11].
Studies published to date have not evaluated the roles of specific
antiretrovirals in the context of a broader examination of classic
risk factors.
Tenofovir can induce proximal renal tubular dysfunction
(PRTD). This specific reabsorption defect of glomerular filtra-
tion products can result in excessive renal phosphate, uric acid,
and bicarbonate losses, as well as proteinuria and glucosuria,
particularly in patients with preexisting nephropathy [12].
PRTD might promote loss of BMD through renal phosphate
wasting [13].
The risk of a fracture in an individual patient not only de-
pends on BMD but is also associated with numerous other
factors, including age, sex, alcohol use, and smoking. The World
Health Organization (WHO) recently issued the FRAX equa-
tion to calculate the 10-year risk of fracture based on key risk
factors [14]. We hypothesized that the comparison between
FRAX- and BMD-derived fracture risks may provide better
insight into the significance of low BMD seen in the context
of long-term antiretroviral treatment (ART) and may help iden-
tify HIV-infected patients at greater risk of fracture at any given
BMD value.
In the current study, we determined the prevalence of low
BMD and its relationship with numerous potential risk factors,
including PRTD, tenofovir, and PI therapy, in a cohort of HIV-
infected adults receiving combined antiretroviral treatment. We
also estimated the 10-year fracture risk.
MATERIALS AND METHODS
Study design and participants. We performed a cross-sec-
tional analysis in a hospital outpatient-based cohort. All pa-
tients who were receiving antiretroviral treatment and attending
the HIV outpatient clinic at St Vincent’s Hospital (Sydney,
Australia) for routine appointments between January and April
2007 were invited to participate, except for those with an active
opportunistic condition. The protocol was approved by the St
Vincent’s Hospital Human Research Ethics Committee. All pa-
tients provided written informed consent.
Assessments. The following were evaluated by means of a
questionnaire administered by a study nurse or physician: pa-
tient characteristics (age, sex, and duration of HIV infection),
body composition (height, weight, body mass index, fat mass
percentage, and lipodystrophy), risk factors for low BMD (pre-
vious fracture, prior fracture in a first-degree relative, smoking
status, corticosteroid use, alcohol consumption, and concom-
itant medications), and type and duration of antiretroviral
treatment.
Blood samples were collected after a minimum 10-h overnight
fast for determination of serum creatinine levels, liver trans-
aminase levels, metabolic parameters (total alkaline phosphatase
[ALP], lactate, glucose, lipids [total, high-density lipoprotein and
low-density lipoprotein cholesterol, and triglycerides]), HIV-re-
lated parameters (CD4+ lymphocyte count and HIV load), and
risk factors for bone disease (calcium, phosphate, bone-specific
ALP [bALP], 25-hydroxyvitamin D, total testosterone, parathy-
roid hormone [PTH], and osteocalcin). Creatinine clearance was
calculated using the Cockcroft Gault formula (calculated glo-
merular filtration rate [GFR]) and analyzed as a continuous var-
iable. From a spot urine sample we measured albumin, creatinine,
glucose, phosphate, and hydroxyproline.
25-Hydroxyvitamin D was quantified using a competitive
protein-binding assay (DiaSorin), total testosterone by radio-
immunoassay (RIA) (ImmunoChem double-antibody testos-
terone iodine 125 RIA kit), PTH by RIA (Siemens Medical
Solutions Diagnostics), osteocalcin by an in-house RIA, and
bALP by Tandem Ostase immunoenzymometric assay (Beck-
man Coulter). The respective lower limits of detection for these
5 assays were 15 nmol/L, 0.1 nmol/L, 1 pmol/L, 3 mg/L, and
0.1 mg/L.
WHO criteria were used to classify patients as having osteo-
porosis (hip or spine T score, 2.5 or less; ie, 2.5 SDs below
the mean BMD value for young adults of the same sex and
race) or osteopenia (hip or spine T score, 1 or less). Patients
classified as osteopenic or osteoporotic were compared with the
“normal BMD group” (hip and spine T score above 1 SD).
The Z score compares the BMD with the mean BMD for in-
dividuals of the same age and sex; any Z score greater than2
was considered to be within the normal range.
PRTD was defined by the presence of 2 of the following
4 pathologies [13]: (1) renal tubular phosphate loss, defined
as a ratio of maximal reabsorption capacity (tubular phosphate)
to GFR of !0.8, as determined with the normogram of Walton
and Bijvoet [15], which corrects the fractional excretion
of phosphate ([phosphateurine/phosphateserum]/[creatinineurine/
creatinineserum]) for the respective serum phosphate level; (2)
a ratio of urine albumin to urine creatinine of 12.5 mg/mmol;
(3) a urine glucose level of 11 mmol/L with a fasting plasma
glucose level of 7.1 mmol/L; and (4) a plasma bicarbonate
level of !20 mmol/L.
When bALP, the hydroxyproline-creatinine ratio, PTH, os-
teocalcin, and 25-hydroxyvitamin D were used as categorical
variables, the upper limits of normal were set at 20.9 mg/L, 15
mmol/mmol, 7 pmol/L, 18.0 mg/L, and 35 nmol/L, respectively.
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Table 1. Baseline Characteristics of Study Patients
Patient characteristics
All patients
(n p 153)
Demographic data
Male sex 150 (98.0)
Age, years 48 (42.5–55.0)
Duration of HIV infection, years 13 (7–19)
Body mass indexa 24.5 (22.5–27.0)
Undetectable HIV RNA level 127 (83.0)
CD4+ cell count, cells/mm3 513 (360–735)
Lipodystrophy at 1 site 92 (60.1)
Creatinine level, mmol/L 83.0 (74.5–93.0)
cGFR, mL/min 103.7 (83.9–122.9)
Risk factors
Previous fracture 52 (34)
Lipid-lowering treatment 40 (26.1)
Antihypertensive treatment 33 (21.6)
Alcohol consumption 13 units/week 74 (48.4)
Smoking, cigarettes per day 15 (5–25)
Coffee consumption, drinks per day 1 (0–2)
Systolic blood pressure, mm Hg 126 (115.5–126.0)
Biological data
Bone ALP level, mg/L, 15.2 (11.9–20.3)
Osteocalcin level, mg/L, 14.0 (10.0–17.5)
25-hydroxyvitamin D level, nmol/L 66.0 (46.0–87.5)
Testosterone level, nmol/L 16.4 (13.1–21.0)
PTH level, pmol/L 4.4 (3.0–6.7)
Hydroxyproline-creatinine ratio,
mmol/mmol 13.2 (10.4–16.1)
Treatment
Tenofovir
History of any use 87 (56.9)
Duration of use, months 28 (16–51)
Currently receiving 67 (43.8)
Duration for current recipients, months 33 (16–53)
Boosted PI
History of any use 103 (67.3)
Duration of use, months 51 (27–77)
Currently receiving 81 (52.9)
Duration for current recipients, months 56 (36.5–80.5)
Zidovudine
History of any use 85 (55.6)
Duration of use, months 35 (10.5–71.0)
Currently receiving 4 (2.6)
Duration for current recipients, months 113.5 (62.3–132.5)
Abacavir
History of any use 88 (57.5)
Duration of use, months 51 (18.0–82.3)
Currently receiving 64 (41.8)
Duration for current recipients, months 54 (18.0–84.8)
NNRTI
History of any use 111 (72.5)
Duration of use, months 58 (28–85)
Currently receiving 74 (48.4)
Duration for current recipients, months 77 (47.8–92.0)
History of any PI use
Lopinavir-ritonavir 58 (37.9)
Indinavir 58 (37.9)
Saquinavir 53 (34.6)
Atazanavir 41 (26.8)
NOTE. Data are no. (%) of patients or median (interquartile range). ALP,
alkaline phosphatase; cGFR, calculated glomerular filtration rate; HIV, human
immunodeficiency virus; IQR, interquartile range; NNRTI, nonnucleoside re-
verse-transcriptase inhibitor; PI, protease inhibitor; PTH, parathyroid hormone.
a Calculated as weight in kilograms divided by the square of height in meters
We defined a boosted PI (bPI) as any HIV PI given with a
ritonavir dose of 100 or 200 mg daily.
Dual-energy x-ray absorptiometry (DXA) was performed on
a GE Lunar Prodigy DXA machine (GE Healthcare; software
version 7.51). The in vivo precision for the bone measurement
using the DXA technique is 0.5%–1.5% at the lumbar spine.
The FRAX tool integrates clinical risk factors (age, sex,
weight, height, previous fracture, parent hip fracture, current
smoking, current glucocorticoid use, rheumatoid arthritis, sec-
ondary osteoporosis, and alcohol use (3 units/day) to produce
a score computed with or without BMD (T score) at the femoral
neck. The FRAX algorithm outputs are the 10-year probabilities
of hip fracture and of a major osteoporotic fracture.
Statistical analysis. All statistical tests were 2-sided, with
a threshold of 5%. Continuous variables are reported using
medians and interquartile ranges, except when stated otherwise.
Logistic regression was used to determine factors associated
with low BMD. Demographic (age, duration of HIV infection
in years, prior fractures, family history of fracture, smoking
status, and alcohol consumption) anthropometric (weight,
height, and body composition parameters), treatment-related
(current use of lipid-lowering drugs, steroids, antihypertensive
therapy, proton pump inhibitors, hormonal substitution or
nonsteroidal anti-inflammatory drugs; current or past use of
tenofovir, zidovudine, abacavir, bPI, or nonnucleoside reverse-
transcriptase inhibitors), HIV-related (CD4+ lymphocyte count
and HIV load) and pathophysiologically plausible biologic var-
iables (cGFR, testosterone, PTH, and 25-hydroxyvitamin D lev-
els) were included in a univariable analysis. All variables with
in the univariable analysis were entered in a multivariableP ! .2
logistic model. The model was adjusted for patient age. FRAX
scores were compared between groups using a 2-sided, non-
parametric Mann-Whitney U test. Statistical analysis was per-
formed using SPSS software, version 15 (SPSS).
RESULTS
Patients. The 153 participants were mostly men with long-
standing HIV infection and a high rate of lipodystrophy (Table
1). Viral replication was undetectable in 127 patients (83%).
Sixty-seven participants (44%) were currently receiving teno-
fovir, 81 (53%) were receiving a bPI, and 40 (26%) were re-
ceiving both tenofovir and a bPI. Eighteen patients (12%) had
low plasma 25-hydroxyvitamin D levels (!35 nmol/L).
Prevalence of low BMD. Sixty-five (42%) patients had low
BMD (osteopenia or osteoporosis), 6 (4%) had osteoporosis,
and 9 (6%) had a Z score less than 2.
Prevalence of PRTD. Eleven patients (7.2%) had PRTD,
all with impaired fractional tubular resorption of phosphorus
and albuminuria; 1 patient also had glucosuria. No patient with
PRTD had a low plasma bicarbonate level. When we alterna-
tively defined PRTD solely on the basis of impaired fractional
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Table 2. Patient Characteristics According to the Presence or Absence of Proximal Tubular Renal Dysfunction (PRTD)
Patient characteristicsa
PRTD present
(n p 11)
PRTD absent
(n p 142) P
Demographic and HIV disease characteristics
Male sex 10 (90.9) 117 (82.4) .695
Age, years 55 (45–58) 48 (42–54) .169
HIV duration, years 21.0 (15.0–23.0) 12.0 (7.0–18.0) .006
Undetectable plasma HIV RNA level 10 (90.9) 117 (82.4) 1.99
CD4+ cell count, cells/mm3 464 (420–620) 517 (360–756) .601
Tenofovir exposure, months 35 (0–48) 0 (0–23) .019
bPI exposure, months 56 (42–92) 23 (0–57) .009
Body composition and bone mineral density
Body mass indexa 24.1 (21.6–24.9) 24.6 (22.9–27.2) .046
Total fat, % 19.0 (17.4–23.6) 21.7 (16.6–26.9) .557
Spine T score 0.80 (1.50 to 0.40) 0.30 (1.30 to 0.70) .454
Hip T score 0.60 (1.30 to 0.20) 0.55 (1.10 to 0.20) .406
Osteopenia (T score less than 1) 6 (66.7)b 59 (45.4)b .304
Bone metabolism, vitamin D, and bone-related hormones
Parathyroid hormone level, pmol/L 3.1 (2.6–6.8) 4.4 (3.1–6.5) .402
Elevated PTH level 2 (18.2) 30 (22.6)b 1.99
bALP level, mg/L 18 (14–23) 15 (12–20) .328
Elevated bALP level 4 (40.0)b 26 (20.3)b .224
Osteocalcin, mg/L 12.3 (10.5–23.3) 14.0 (10.0–17.4) .811
Elevated osteocalcin level 3 (27.3) 28 (21.2)b .704
Hydroxyproline-creatinine ratio 15.2 (11.4–19.3) 13.01 (10.41–16.0) .154
Elevated hydroxyproline-creatinine ratio 6 (54.5) 46 (34.6)b .205
Plasma 25-hydroxyvitamin D level, nmol/L 88 (48–101) 66 (45–81) .388
Low plasma 25-hydroxyvitamin D level 1 (9.1) 17 (12.7)b 1.99
cGFR 68.1 (54.4–82.7) 104.9 (87.6–123.7) .002
NOTE. Data are no. (%) of patients or median (interquartile ranges). Statistically significant P values are shown in boldface font. BALP, bone
alkaline phosphatase; bPI, boosted protease inhibitor; cGFR, calculated glomerular filtration rate; HIV, human immunodeficiency virus; NNRTI, non-
nucleoside reverse-transcriptase inhibitor; PTH, PI, protease inhibitor; PTH, parathyroid hormone.
a Calculated as weight in kilograms divided by the square of height in meters
b Percentages were calculated using the number of patients with available data as the denominator.
tubular resorption of phosphorus in a post hoc analysis, we
identified 27 patients (17.6%).
PRTD was associated with a longer duration of HIV infection
and longer exposure to tenofovir (with 8 of the 11 patients
with PRTD exposed to tenofovir for 2 years) or bPIs (Table
2). BMD was slightly lower and cGFR significantly decreased
in patients with PRTD ( ). Seven of the 11 patientsPp .002
(64%) had evidence of altered bone metabolism with either
increased osteoclast activity (hydroxyproline-creatinine ratio)
(6 patients [55%]), increased osteoblast activity (osteocalcin
and/or bALP) (5 patients [46%]), or both (4 patients [37%]).
Of the 27 patients with increased fractional excretion of phos-
phorus, 5 (19%) had elevated plasma PTH, 16 (59%) had evi-
dence of altered bone metabolism, and 14 (52%) had low BMD;
18 (67%) had been exposed to tenofovir for a median of 33.5
months.
Risk factors for low BMD. Univariable analysis revealed
that patients with higher body mass index (OR, 0.87; 95%
confidence interval [CI], 0.77–0.98), higher testosterone levels
(OR, 0.94; 95% CI, 0.89–0.99), or higher creatinine clearance
(OR, 0.99; 95% CI, 0.97–1.00) were less likely to have low BMD;
any use of bPI, however, was significantly associated with low
BMD (OR, 2.83; 95% CI, 1.36–5.92) (Table 3). Current te-
nofovir, bPI, thymidine analogue, abacavir, or nonnucleoside
reverse-transcriptase inhibitor therapy; current lipodystrophy;
and use of concomitant medications were not significant. In
multivariable analysis, the history of any use of bPI remained
significant (OR, 3.10; 95% CI, 1.30–7.21). Higher testosterone
levels were also a significant protective factor (OR, 0.93; 95%
CI, 0.88–0.99). Of note, “classic” risk factors, such as prior
fracture, use of steroids, and alcohol consumption, were not
risk factors for low BMD after adjustment for combination
antiretroviral therapy exposure.
BMD and bone metabolism by antiretroviral treatment
exposure. Low BMD was consistently more frequent in pa-
tients treated with tenofovir or bPI, but differences only reached
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Table 3. Parameters Associated with Low Bone Mineral Density (T score less than 1)
Characteristic
Univariable analysis Multivariable analysisa
OR (95% CI) P OR (95% CI) P
Agea 1.01 (0.98–1.05) .415 1.04 (0.99–1.10) .113
Body mass index 0.87 (0.77–0.98) .018 0.87 (0.74–1.02) .094
Current antihypertensive therapy 0.55 (0.24–1.26) .156 0.46 (0.17–1.27) .133
cGFR 0.99 (0.97–1.00) .043 0.99 (0.97–1.01) .565
Testosterone level 0.94 (0.89–0.99) .022 0.93 (0.88–0.99) .027
PRTDa 2.40 (0.57–10.04) .331 1.54 (0.29–8.29) .613
Tenofovir (history of any use) 1.58 (0.81–3.11) .181 1.32 (0.60–2.92) .488
bPI (history of any use) 2.83 (1.36–5.92) .006 3.10 (1.30–7.21) .011
NNRTI (history of any use) 0.54 (0.25–1.15) .109 0.49 (0.20–1.16) .106
NOTE. Statistically significant P values are shown in boldface font. BPI, boosted PI; cGFR, calculated
glomerular filtration rate; CI, confidence interval; NNRTI, nonnucleoside reverse-transcriptase inhibitor; OR,
odds radio; PRTD, proximal renal tubular dysfunction.
a Analyses have been adjusted for age and PRTD.
statistical significance for the Z score in bPI recipients, the spine
T and Z scores in bPI recipients, and the hip Z and T scores
in tenofovir recipients (Table 4). Levels of ALP (data not
shown), its bone isoenzyme (bALP), osteocalcin, and urinary
hydroxyproline excretion were significantly higher in individ-
uals receiving tenofovir ( ), suggesting increases in bothP .002
osteoblast and osteoclast activity. Interestingly, among 48 (35%)
of 138 patients with elevated bALP or osteocalcin levels, 32
(68%) of 47 also had a high urinary hydroxyproline levels.
Among the 52 (36%) of 144 patients with elevated urine hy-
droxyproline levels, 32 (63%) of 51 had elevated levels of bALP
or osteocalcin. There was also a trend toward higher PTH levels
in tenofovir-treated patients ( ). Patients currently re-Pp .07
ceiving bPI were more likely to have elevated plasma osteocalcin
levels ( ), but ALP and bALP and the hydroxyproline-Pp .004
creatinine ratio did not change significantly. There was no sig-
nificant relationship between bPI duration ( , by testPp .194
for trend) or tenofovir duration ( , by test for trend)Pp .731
and the prevalence of low BMD. Remarkably, significantly fewer
patients treated with TDF showed a pathological fractional ex-
cretion of phosphate.
Ten-year estimation of fracture risk. The FRAX score com-
puted without BMD provided similar fracture risks for patients
with normal BMD and those with low BMD (Table 5). The
inclusion of BMD data in the equation significantly increased
the calculated risk of fractures in patients with osteopenia,
whereas it significantly reduced fracture risks of patients with
normal BMD. The mean 10-year risk of fracture of the whole
study population estimated by the FRAX equation (computed
with the BMD) was 1.2% for hip fracture and 5.4% for major
osteoporotic fracture.
Twenty-two (15.8%) of 139 patients had a 10-year probability
of a major osteoporotic fracture of 17.5% (the threshold at
which bisphosphonate therapy is considered to be cost-effective
[16]), and only 3 (2.2%) had a 10-year probability of major
osteoporotic fracture of 120%. We compared the characteristics
of patients with a FRAX score above the 7.5% threshold with
those of the rest of the study population. We did not find any
significant difference between these 2 groups with regard to
risk factors, demographic characteristics, renal function, or du-
ration of antiretroviral treatment by class (data not shown).
DISCUSSION
In agreement with other studies, we found low BMD to be
common in HIV-infected men, with 47% of patients having
WHO-defined osteopenia or osteoporosis [1]. Use of a bPI was
independently associated with low BMD. Few studies have
looked at BMD after adjustment for HIV-independent risk fac-
tors, HIV-related parameters, and antiretroviral treatment char-
acteristics. A meta-analysis of 12 cross-sectional studies cal-
culated a pooled OR for low BMD of 1.57 for PI-treated versus
PI-untreated patients [17]. However, concomitant disease and
treatment variables were not evaluated. Recently, osteopenia
was found to be more common in premenopausal HIV-infected
women receiving PI-based therapy (17%) than in premeno-
pausal, uninfected women (7%) [18]. In the Aquitaine cohort
an association was reported between BMD and nadir CD4+ cell
count in women, but, again, no adjustment for known risk
factors was performed [19].
In contrast, we assessed the risk for low BMD adjusted for
a large range of classic, HIV-related, and antiretroviral treat-
ment variables, including PRTD. Only bPIs and low testoster-
one remained significantly associated with low BMD in mul-
tivariable analysis, suggesting a causative role for PIs in the
pathogenesis of osteopenia in patients with stable, mostly vi-
rologically suppressed HIV disease. With !10% of our study
population having severe immunosuppression (CD4+ cell
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Table 4. Patient Characteristics, According to Current Tenofovir (TDF) or Boosted Protease Inhibitor (bPI) Exposure
Patient characteristica
Current TDF exposure Current bPI exposure
Yes
(n p 67)
No
(n p 86) P
Yes
(n p 81)
No
(n p 72) P
Demographic and HIV disease
Male sex 66 (98.5) 84 (97.7) 1.99 78 (96.3) 72 (100) .248
Age, years 47 (42–55) 49 (43–55) .354 47 (43–54) 49.5 (42–57) .538
HIV infection duration, years 14 (7–20) 12 (6.8–17.3) .433 15 (9–20) 10 (5.3–16.0) .003
Undetectable HIV RNA level 56 (83.6) 71 (82.6) .867 68 (84) 59 (81.9) .742
CD4+ cell count, cells/mm3 480 (330–696) 537 (430–780) .044 504 (350–708) 519 (410–766) .465
Body composition and BMD
Body mass indexa 24.8 (22.9–27.2) 24.3 (22.5–26.6) .325 24.8 (22.7–27.4) 24.3 (22.5–26.5) .445
Total fat, % 21.4 (18.0–27.4) 21.3 (16.2–26.8) .315 21.0 (17.1–28.5) 21.8 (16.4–25.3) .561
Leg fat, % 15.8 (11.0–21.3) 15.5 (9.1–21.0) .694 15.6 (8.4–23.6) 15.6 (12.2–19.5) .504
Trunk fat, % 26.5 (22.1–33.1) 26.4 (20.4–33.0) .459 25.8 (22.0–34.5) 27.1 (19.5–31.5) .633
Spine T score 0.6 (1.6 to 0.5) 0.1 (1.1 to 0.8) .103 0.6 (1.6 to 0.4) 0.1 (0.9 to 0.9) .032
Spine Z score 0.2 (1.3 to 0.6) 0.2 (0.6 to 1.1) .050 0.1 (1.4 to 0.6) 0.2 (0.6 to 1.1) .021
Hip T score 0.8 (1.4 to 0.2) 0.4 (1.0 to 0.4) .010 0.7 (1.4 to 0.0) 0.5 (1.0 to 0.3) .208
Hip Z score 0.3 (1.0 to 0.3) 0.3 (0.6 to 0.7) .003 0.2 (0.9 to 0.5) 0.0 (0.6 to 0.7) .137
Osteopenia according to T
score, no. (%) 30 (52.6)b 35 (42.7)b .248 39 (53.4)b 26 (39.4)b .098
Z score less than 2 SDs 6 (10.5)b 3 (3.7)b .160 8 (11.0)b 1 (1.5)b .035
BMD 1.18 (1.11–1.23) 1.19 (1.12–1.23) .532 1.18 (1.11–1.22) 1.20 (1.12–1.26) .041
Bone metabolism, vitamin D,
and bone-related hormones
Bone ALP level, mg/L 17.1 (13.6–22.8) 13.8 (11.1–17.6) .002 15.6 (12.0–21.1) 15.0 (11.7–17.4) .218
Osteocalcin level, mg/L 14.6 (11.3–20.2) 12.8 (9.0–15.8) .004 14.2 (11.0–20.4) 12.5 (12.5–18.3) .004
Hydroxyproline-creatinine ratio 15.4 (12.9–18.6) 11.3 (9.5–14.4) !.001 13.7 (11.0–17.5) 11.8 (9.6–15.7) .057
Plasma 25-hydroxyvitamin D
level, nmol/L 68.0 (49–95) 62.5 (42.8–79.0) .183 69 (51.5–89.0) 60 (41–81) .102
Testosterone level, nmol/L 17.1 (13.4–21.7) 16.0 (12.9–19.0) .202 16.4 (12.5–21.7) 16.5 (14.1–20.8) .647
PTH level, pmol/L 4.9 (3.3–7.3) 4.1 (2.8–6.1) .065 4.7 (3.1–7.0) 4.2 (2.8–6.3) .336
Renal function
cGFR 101.3 (82.6–130.2) 105.3 (84.5–119.7) .966 105.4 (82.8–121.5) 101.1 (83.0–127.5) .766
PRTD 7 (10.5)b 4 (4.7) .213 8 (9.9) 3 (4.2) .219
Pathologic fractional excretion
of phosphate 4 (6.8) 16 (19.8) .030 11 (14.9) 9 (13.6) .836
NOTE. Data are no. (%) of patients or median (interquartile ranges). Statistically significant P values are shown in boldface font. ALP, alkaline phosphatase;
BMD, bone mineral density; cGFR, calculated glomerular filtration rate; HIV, human immunodeficiency virus; PRTD, proximal renal tubular disease; PTH, parathyroid
hormone; SD, standard deviation.
a Calculated as weight in kilograms divided by the square of height in meters
b Percentages were calculated using the number of patients with available data as the denominator.
count, !200 cells/mL), and 83% having suppressed viremia, it
is difficult to conclude that HIV replication and disease severity
are important contributors to the observed low BMD in our
population. PI-associated loss of BMD may be due to altered
1,25-dihydroxyvitamin D3 production [20] or stimulated os-
teoclast or inhibited osteoblast activity [21, 22]. Although low
BMD is also found in untreated HIV-infected individuals, a
randomized prospective study demonstrated greater BMD loss
with continuous antiretroviral treatment than with intermittent
antiretroviral treatment [23]. A recent study showed a median
decrease of 4.1% in lumbar spine BMD and 2.7% in hip BMD
48 weeks after antiretroviral treatment initiation, with greater
decrements in the PI-treated patients [24]. Another study ex-
amined the change in total BMD in HIV-infected persons ran-
domized to efavirenz or lopinavir-ritonavir. There was an av-
erage 2.4% loss in BMD during a period of 96 weeks, regardless
of treatment. Interestingly, the switch to bPI monotherapy after
24 weeks was not associated with improvement in BMD [25].
The effect of PIs on BMD has been controversial. Earlier
cross-sectional studies suggesting a negative PI effect were not
adjusted for HIV-independent and HIV-related confounding
factors. Moreover, individual PIs may have differential effects
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Table 5. Ten-Year Fracture Risks for Patients with or without Low Bone Mineral Density (BMD), According to FRAX Scores Computed
with or without BMD
Fracture risk
Patients with normal BMD
(n p 74)
Patients with low BMD
(n p 65)
Overall population
(n p 139)
FRAX score
computed with-
out BMD
FRAX score
computed with
BMD P
FRAX score
computed
without BMD
FRAX score
computed
with BMD P
FRAX score
computed with-
out BMD
FRAX score
computed with
BMD P
Hip fracture risk 0.40 (0.20–1.00) 0.20 (0.10–0.50) !.001 0.40 (0.20–1.20) 0.90 (0.50–2.40) !.001 0.40 (0.20–1.00) 0.50 (0.10–1.00) .575
Major osteoporotic
fracture risk 4.10 (2.90–6.00) 3.55 (2.70–5.20) !.001 3.80 (2.60–6.90) 4.80 (3.80–7.90) !.001 4.40 (2.90–6.40) 4.10 (2.90–6.20) .467
NOTE. Data are median (interquartile range), unless otherwise indicated. Low BMD was defined as a T score lower than 1 SD below the mean. P values
refer to the difference between the fracture risks computed with and without BMD.
on BMD. Our results reinforce the possible role of bPI in re-
ductions in BMD [26].
Although T and Z scores for both hip and spine were con-
sistently lower and osteopenia more prevalent in patients re-
ceiving tenofovir-based regimens, we could not demonstrate a
statistically significant association between current or cumu-
lative tenofovir use and osteopenia or osteoporosis. The lack
of significance despite this consistent pattern may be due to
the relative short median tenofovir exposure time (28 months),
which is only approximately one-half the median PI exposure
time. Thus, exposure time may have been too short to result
in significant quantitative differences in BMD. This concern is
nourished by the significant higher osteoblast and osteoclast
activity in tenofovir recipients, which, together with a trend for
increased PTH levels, might indicate developing osteomalacia.
To clarify these concerns, long-term follow-up data are needed.
Tenofovir has been associated with renal tubular toxicity and
subsequent renal phosphate wasting [27]. Renal phosphate
wasting may lead to increased bone turnover and hence elevated
serum ALP. Significant tenofovir-related increases in ALP were
identified after the initiation of tenofovir-based antiretroviral
treatment but not tenofovir-sparing regimens in both treat-
ment-naive and treatment-experienced patients [28].
Eleven patients (7.2%) had PRTD, which did not correlate
with low BMD in multivariable analysis. The discriminatory
power of the study for PRTD was limited by the lack of in-
formation on proteinuria (rather than albuminuria) or specific
markers for tubular proteinuria. However, excessive phospha-
turia in the fasting state and in the absence of vitamin D or
PTH disturbances—as documented in our patients—is con-
sidered highly specific for proximal renal tubulopathy. Fur-
thermore, HIV-associated nephropathy and diabetes mellitus,
2 main causes of nontubular proteinuria, were not evident in
our patients. We therefore believe that PRTD truly represents
tubolopathy. When we alternatively defined PRTD solely on
the basis of impaired fractional tubular resorption of phos-
phorus in a post hoc analysis, we identified 27 patients (17.6%);
the fact that most of them had no hyperparathyroidism suggests
that a mild form of tubulopathy was present in these patients.
Again, there was no association between osteopenia and alter-
ations in bone metabolism (data not shown).
In the current era, with a growing proportion of HIV-infected
persons aged 150 years, bone health is becoming a more im-
portant comorbid factor. It is unclear whether the high rates
of osteopenia in men !50 years old will translate into increased
fracture rates after an additional 10–20 years of antiretroviral
treatment. A very large cohort study recently reported fracture
prevalence to be 160% greater in HIV-infected adults than in
HIV-uninfected adults [29]. BMD screening may be even more
relevant as effective therapies become available. For example,
the use of intravenous zoledronate appears to be a well tolerated
and effective therapy for HIV-associated bone loss [30, 31].
Although the National US Osteoporosis Foundation does not
recommend BMD screening for all patients with HIV, it ex-
plicitly states that postmenopausal women and men 150 years
of age should be considered for BMD testing if the risk factor
profile suggests cause for concern [32].
To improve the ability to predict subsequent fragility fracture
in our patients, we used the WHO FRAX equation [14]. There
are different recommendations for defining the threshold at
which antiresorptive treatment is recommended. British guide-
lines recommend using a threshold based on age—that is, 7.5%
for a man 45 years of age; this recommendation could translate
into treatment for up to 16% of our HIV-infected population,
significantly more than the 4.3% identified by documented
osteoporosis only [16]. The National Osteoporosis Foundation
recommendations suggest treating only patients with a risk for
major osteoporotic fracture above a threshold of 20% at 10
years, meaning that only one-half of the patients (2.2% vs 4.3%)
with osteoporosis would be identified [32]. In a relatively young
population such as ours, with well-identified nonclassic risk
factors (chronic disease, antiretroviral therapy), use of an age-
dependent threshold as in the British recommendations may
be more appropriate.
The FRAX score computed without BMD seems unable to
discriminate adequately between patients with and those with-
Low BMD, Renal Dysfunction, and Fractures in HIV • JID 2009:200 (1 December) • 1753
out osteopenia, and its guidance on when to initiate antire-
sorptive therapy is highly dependent on the chosen threshold,
with such therapy recommended for 2.2% of our population
at a 20% ten-year risk of major osteoporotic fracture, and 16%
at a 7.5% ten-year risk.
Considering that the FRAX score includes only classic, HIV-
independent risk factors and that HIV positivity and treatment
have been associated with lower BMD, the score provides a
very conservative fracture risk estimate for HIV-positive pop-
ulations. Similar to rheumatoid arthritis, HIV infection pro-
motes a chronic inflammatory state that may turn out to be
an independent risk factor for bone fracture to be included in
a FRAX-like score.
Taken together, these observations argue for using a FRAX
score computed without BMD only as a screening tool in all
HIV-positive patients with no indications for DXA scanning.
Given our findings and published data, BMD measurement may
be appropriate for HIV-positive postmenopausal women and
men 150 years of age, all HIV-positive patients with docu-
mented hypogonadism, and bPI and/or tenofovir recipients.
This study has several limitations resulting from its cross-
sectional nature. In particular, antiretroviral treatment regimens
had not been chosen randomly, and drug-independent effects
on BMD or bone metabolism may therefore have been falsely
attributed to bPI or tenofovir treatment. The effect of insuf-
ficient vitamin D or testosterone levels as well as low body mass
index may be obscured by the low rate of pathologic values
found in the study population. Moreover, the use of the FRAX
tool has not been validated for young HIV-positive individuals
or for Australians. Given the epidemiology in Australia, our
study results apply only to HIV-positive male patients and
therefore cannot be generalized to women.
In conclusion, we found a high prevalence of low BMD in
HIV-infected adults receiving combination antiretroviral ther-
apy, particularly in those receiving a bPI. The use of a tool such
as the WHO FRAX tool warrants further validation studies in
HIV-infected patients.
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